BPC-157 and TB-500: What the FDA's 2026 Compounding Vote Actually Means for Patients
In July 2026, an FDA advisory committee voted 8-6 to recommend BPC-157 and TB-500 for the list of substances licensed 503A pharmacies can compound. That vote is a nonbinding recommendation, not FDA approval — neither peptide is legally compoundable yet. Here's exactly what changed, what hasn't, and how Roots is approaching peptide therapy while the rulemaking plays out.
What the FDA's advisory committee actually voted on
At a two-day meeting on July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides being considered for Section 503A's Bulk Drug Substances List — the list that determines which raw ingredients state-licensed compounding pharmacies are permitted to use. BPC-157, TB-500 and KPV were each recommended by a vote of 8-6 with one abstention on the first day; MOTS-c followed 7-5. Semax and Epitalon passed by similarly narrow margins on day two. Only one peptide under review, Emideltide, was voted down. Notably, the committee went against the recommendation of FDA's own staff, who had argued against advancing all seven.
A recommendation is not approval
It's worth being precise about what did and didn't happen. The committee's vote is advisory and nonbinding — the FDA itself still has to decide whether to accept it, and historically, adding a substance to the 503A Bulks List requires formal notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule. That process has typically taken twelve months or more. Industry coverage of the vote has placed realistic pharmacy availability, if the FDA proceeds at all, at late 2026 at the very earliest and more plausibly sometime in 2027. A separate, earlier step mattered too: in April 2026, the FDA removed BPC-157 and TB-500 from its Category 2 list of "bulk drug substances that raise significant safety concerns," which is what cleared the way for July's review to happen. That removal is a meaningful signal, but the FDA has been explicit that it does not, on its own, establish eligibility for compounding.
What BPC-157 and TB-500 are commonly discussed for
Online and in patient conversations, both peptides are frequently discussed in connection with soft-tissue recovery and general tissue-repair support — the kind of interest that's driven a noticeable spike in patients searching for information and asking clinics about them directly. BPC-157 was reviewed by the FDA panel in the context of ulcerative colitis; TB-500 in the context of wound healing. FDA's own review flagged open questions that matter here: immunogenicity, impurity profiles, and limited human exposure data. That's a reason for measured expectations, not firm claims — nothing about either peptide is settled science, and any specific outcome promised to you online should be treated skeptically.
Why this still matters even though nothing is available yet
Patient interest in BPC-157 and TB-500 has outpaced the regulatory process, and that gap is exactly where risk concentrates. Faced with a "not yet legal" answer from licensed providers, some people turn to online sellers marketing these peptides as "research use only" — language that exists specifically so sellers can avoid FDA oversight. Research-only vials aren't compounded in a licensed pharmacy, aren't tested for sterility, potency or endotoxins, and come with no pharmacist or physician monitoring. We've written before about why Roots only uses pharmaceutical-grade peptides, and that reasoning applies with extra force here: the regulatory spotlight on BPC-157 and TB-500 exists partly because of safety questions the agency hasn't finished answering.
How Roots is approaching this
Today, Roots does not prescribe or source BPC-157 or TB-500 for any patient, under any circumstance — that's a firm line regardless of demand, and it will stay that way until the FDA formally adds both peptides to the 503A Bulks List and licensed pharmacies have a lawful path to compound them. In the meantime, we already offer other pharmaceutical-grade peptides sourced from a licensed, FDA-regulated 503A pharmacy for patients whose labs, history and goals support them. Our clinical team is tracking the FDA's rulemaking process closely, and if and when compounding becomes lawful, we'll evaluate BPC-157 and TB-500 the same way we evaluate every protocol here — through bloodwork and a consultation, not a trend. If you're curious about recovery-focused or wellness peptide therapy, the most useful next step is a conversation about what's appropriate and legally available today. Outcomes vary by patient, and candidacy for any peptide protocol is confirmed at consultation.
Frequently asked questions
Are BPC-157 and TB-500 FDA-approved?
No. Neither is an FDA-approved drug, and as of October 2026 neither has been formally added to the FDA's Section 503A Bulk Drug Substances List — the list that determines which ingredients licensed compounding pharmacies may legally use. An FDA advisory committee voted in July 2026 to recommend both for that list, but the FDA has not yet acted on the recommendation.
What exactly did the FDA's advisory committee vote on in July 2026?
At a July 23-24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides being considered for the 503A Bulks List. BPC-157 and TB-500 were each recommended 8-6 with one abstention, alongside KPV — going against FDA staff, who had recommended against all seven. The vote is a nonbinding recommendation, not a rule change.
Can I get BPC-157 or TB-500 prescribed at Roots right now?
Not currently. Until the FDA formally adds these peptides to the 503A Bulks List and completes the rulemaking that would let licensed pharmacies compound them, Roots does not prescribe or source BPC-157 or TB-500 for patients. We already offer other pharmaceutical-grade peptides sourced from a licensed 503A pharmacy, and we're monitoring this rulemaking process closely.
What are BPC-157 and TB-500 generally discussed for?
Online and in patient conversations, both are frequently discussed in connection with soft-tissue recovery and general tissue-repair support. The FDA's own review raised open questions about immunogenicity, impurity profiles and limited human exposure data, so any specific claim about what either peptide does for a given person should be treated with caution until the regulatory and research picture is clearer.
Is it safe to buy BPC-157 or TB-500 online in the meantime?
We'd urge real caution. Products sold online as "research-only" aren't manufactured for human use, aren't tested for sterility or potency, and come with no prescribing or pharmacist oversight. That's true of any peptide sourced that way — not just these two — which is why Roots only ever sources peptides, once they're lawfully available, from licensed, FDA-regulated 503A pharmacies.